RNRie Louise Møller Nordestgaard

Rie Louise Møller Nordestgaard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rie Louise Møller Nordestgaard has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Johan Burisch

    Gastro Unit Medical Section Copenhagen University Hospital—Amager and Hvidovre Hvidovre Denmark

    3 shared publications
  • Johan Burisch

    Gastrounit, Medical Division Copenhagen University Hospital—Amager and Hvidovre Hvidovre Denmark

    2 shared publications
  • Mads Damsgaard Wewer

    Gastrounit, Medical Division, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark; Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents, and Adults, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark

    2 shared publications
  • Mads Damsgaard Wewer

    Gastro Unit, Medical Section, Copenhagen University Hospital - Amager and Hvidovre 5 , Hvidovre

    2 shared publications
  • Mikkel Malham

    Department of Paediatrics and Adolescent Medicine Hvidovre Hospital, University of Copenhagen Hvidovre Denmark

    2 shared publications
  • Trine Boysen

    Gastrounit, Medical Section, Copenhagen University Hospital, Amager and Hvidovre, Hvidovre, Denmark

    2 shared publications

Latest Publications

  • Open Access

    Clinical Trial: Evaluating a Single 1600 mg Tablet Regimen of 5‐Aminosalicylate for Ulcerative Colitis—The EASI Trial

    by Rie Louise Møller Nordestgaard, Bobby Lo, Rosalina Bergstrøm, Izabella Adzioski, Helene Skotte, Ida Marie Hawwa, Signe Krogsgaard Holme, Bermal Tiftikci, Katarzyna Majchrzak, Ida Vind, et al.

    Background: 5‐Aminosalicylate (5‐ASA) is recommended for the treatment of mild‐to‐moderate ulcerative colitis (UC). However, adherence may be low; poor adherence is associated with an increased risk for flares.Aim: To investigate whether a regimen of a single 1600 mg tablet of 5‐ASA improves adherence with preserved remission rates compared to a conventional regimen of three 800 mg tablets.Methods: We enrolled 178 patients with UC (89 per group) in this open‐label randomised controlled phase IV trial. Patients had to have stable remission on 5‐ASA for at least 2 months and no concomitant diseases that could affect compliance. We randomised patients (1:1) to either receive Asacol 1600 mg single tablet or Asacol 2400 mg (three tablets of 800 mg once daily) for 12 months. Patients were assessed five times during the 12 months, where medicine was delivered and received, blood and stool samples were collected and symptom scores were determined.Results: Eighty‐two patients taking a single tablet and 78 taking three tablets were adherent (p = 0.32). Fewer patients in the 1600 mg group missed doses (24.5 vs. 26.5). There was no difference in the number of relapses or proportions experiencing relapse. Neither adherence nor treatment group was a significant predictor of relapse.Conclusion: The single‐tablet lower dose treatment could be a feasible alternative to the conventional three‐tablet regimen.Trial Registration: The study was registered at Clinicaltrials.gov (ID NCT04133194) and approved by The Danish Medicine Agency and The National Committee on Health Research Ethics (EudraCT 2019‐002070‐31)

  • Too Old to Treat? Rethinking Steroid-sparing Therapy in Elderly-onset Inflammatory Bowel Disease

    by Rie Louise Møller Nordestgaard, Mads Damsgaard Wewer, Johan Burisch

  • Editorial: Treatments for inflammatory bowel disease across age‐spectrum—Are they the same? Authors' reply

    by Mads Damsgaard Wewer, Rie Louise Møller Nordestgaard, Mikkel Malham, Vibeke Wewer, Trine Boysen, Johan Burisch

    LINKED CONTENT: This article is linked to Nordestgaard et al papers. To view these articles, visit https://doi.org/10.1111/apt.18106 and https://doi.org/10.1111/apt.18143

  • Open Access

    Treatment of inflammatory bowel disease with steroid‐sparing medications is age‐dependent – Results from a Danish nationwide cohort study, 2000–2018

    by Rie Louise Møller Nordestgaard, Mads Damsgaard Wewer, Mikkel Malham, Vibeke Wewer, Trine Boysen, Johan Burisch

    Summary: Background: Paediatric‐onset and elderly‐onset inflammatory bowel disease (IBD) present unique treatment challenges.Aims: We investigated treatment patterns following a first and second course of systemic steroids in paediatric‐ and elderly‐onset IBD and compared them to adult‐onset IBD.Methods: All patients diagnosed with Crohn's disease (CD) or ulcerative colitis (UC) between 2000 and 2018 were identified through the Danish healthcare registries. Patients were divided into groups based on their age at diagnosis. Kaplan–Meier plots were prepared for medications and surgeries after diagnosis and after the first and second courses of systemic steroids. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated using multivariate Cox regression analysis for steroid‐sparing medications.Results: 1851 CD (13%) and 1687 (6%) UC patients were paediatric‐onset, while 2952 (20%) CD and 5812 (23%) UC patients were elderly‐onset. Paediatric‐onset more frequently received immunomodulators [CD: HR: 1.64, CI: 1.52–1.77, UC: HR: 2.29, CI: 2.02–2.61] and biologics [CD: HR: 1.43, CI: 1.25–1.65, UC: HR: 1.27, CI: 0.99–1.64], while elderly‐onset less frequently received immunomodulators [CD: HR: 0.39, CI: 0.35–0.44, UC: HR: 0.58, CI: 0.50–0.67] and biologics [CD: HR: 0.19, CI: 0.14–0.25, UC: HR: 0.36, CI: 0.27–0.48] compared to adult‐onset age groups. After two courses of systemic steroids, elderly‐onset still received less steroid‐sparing medications. High frailty was associated with lower usage of medications for elderly‐onset.Conclusion: There are significant differences in the use of steroid‐sparing medication between age of onset, even after two courses with systemic steroids. High frailty could account for some of these differences in elderly‐onset IBD.


  • Re-resection Rates and Disease Recurrence in Crohn’s Disease: A Population-based Study Using Individual-level Patient Data

    by Anja Poulsen, Julie Rasmussen, Mads Damsgaard Wewer, Esben Holm Hansen, Rie Louise Møller Nordestgaard, Hans Søe Riis Jespersen, Dagmar Christiansen, Elena Surnacheva, Viviane Annabelle Lin, Nurcan Aydemir, et al.

    Despite advances in the medical treatment of Crohn’s disease [CD], many patients will still need bowel resections and face the subsequent risk of recurrence and re-resection. We describe contemporary re-resection rates and identify disease-modifying factors and risk factors for re-resection. We conducted a retrospective, population-based, individual patient-level data cohort study covering 47.4% of the Danish population, including all CD patients who underwent a primary resection between 2010 and 2020. Among 631 primary resected patients, 24.5% underwent a second resection, and 5.3% a third. Re-resection rates after 1, 5, and 10 years were 12.6%, 22.4%, and 32.2%, respectively. Reasons for additional resections were mainly disease activity [57%] and stoma reversal [40%]. Disease activity-driven re-resection rates after 1, 5, and 10 years were 3.6%, 10.1%, and 14.1%, respectively. Most stoma reversals occurred within 1 year [80%]. The median time to recurrence was 11.0 months. Biologics started within 1 year of the first resection revealed protective effect against re-resection for stenotic and penetrating phenotypes. Prophylactic biologic therapy at primary ileocaecal resection reduced disease recurrence and re-resection risk (hazard ratio [HR] 0.58, 95% confidence interval [CI] [0.34-0.99], p = 0.047). Risk factors for re-resection were location of resected bowel segments at the primary resection, disease location, disease behaviour, smoking, and perianal disease. Re-resection rates, categorised by disease activity, are lower than those reported in other studies and are closely associated with disease phenotype and localisation. Biologic therapy may be disease-modifying for certain subgroups when initiated within 1 year of resection.